{"id":"https://openalex.org/W7224867995","doi":"https://doi.org/10.4103/ijd.ijd_948_25","title":"Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study","display_name":"Effectiveness and Safety of Off-label Tofacitinib Use for Atopic Dermatitis, Alopecia Areata and Plaque Psoriasis: An Observational Study","publication_year":2026,"publication_date":"2026-10-30","ids":{"openalex":"https://openalex.org/W7224867995","doi":"https://doi.org/10.4103/ijd.ijd_948_25"},"language":"en","primary_location":{"id":"doi:10.4103/ijd.ijd_948_25","doi":"https://doi.org/10.4103/ijd.ijd_948_25","is_oa":true,"landing_page_url":"https://doi.org/10.4103/ijd.ijd_948_25","pdf_url":null,"source":{"id":"https://openalex.org/S40624954","display_name":"Indian Journal of Dermatology","issn_l":"0019-5154","issn":["0019-5154","1998-3611"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320448","host_organization_name":"Medknow","host_organization_lineage":["https://openalex.org/P4310320448","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Medknow","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Indian Journal of Dermatology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://doi.org/10.4103/ijd.ijd_948_25","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5139973483","display_name":"Saumya Panda","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Saumya Panda","raw_affiliation_strings":["From the Department of Dermatology, Jagannath Gupta Institute of Medical Sciences and Hospital, Kolkata, West Bengal, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"From the Department of Dermatology, Jagannath Gupta Institute of Medical Sciences and Hospital, Kolkata, West Bengal, India","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160160368","display_name":"Titas Panda","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100047","display_name":"Institute of Post Graduate Medical Education and Research","ror":"https://ror.org/00ysvbp68","country_code":"IN","type":"education","lineage":["https://openalex.org/I226431899","https://openalex.org/I4210100047"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Titas Panda","raw_affiliation_strings":["Department of Community Medicine Internship, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Community Medicine Internship, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India","institution_ids":["https://openalex.org/I4210100047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5118136812","display_name":"Shreya Kotal","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210100047","display_name":"Institute of Post Graduate Medical Education and Research","ror":"https://ror.org/00ysvbp68","country_code":"IN","type":"education","lineage":["https://openalex.org/I226431899","https://openalex.org/I4210100047"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Shreya Kotal","raw_affiliation_strings":["Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India","institution_ids":["https://openalex.org/I4210100047"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5061560811","display_name":"Suparna Chatterjee","orcid":"https://orcid.org/0000-0003-1156-5130","observed_orcids":["https://orcid.org/0000-0003-1156-5130"]},"institutions":[{"id":"https://openalex.org/I4210100047","display_name":"Institute of Post Graduate Medical Education and Research","ror":"https://ror.org/00ysvbp68","country_code":"IN","type":"education","lineage":["https://openalex.org/I226431899","https://openalex.org/I4210100047"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Suparna Chatterjee","raw_affiliation_strings":["Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India","institution_ids":["https://openalex.org/I4210100047"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.87658892,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10837","display_name":"Dermatology and Skin Diseases","score":0.8701000213623047,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10469","display_name":"Psoriasis: Treatment and Pathogenesis","score":0.11069999635219574,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11167","display_name":"Hair Growth and Disorders","score":0.007799999788403511,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":1.0},{"id":"https://openalex.org/keywords/off-label-drug-use","display_name":"off-label drug use","score":0.9760000109672546},{"id":"https://openalex.org/keywords/alopecia-areata","display_name":"alopecia areata","score":0.8999999761581421},{"id":"https://openalex.org/keywords/plaque-psoriasis","display_name":"plaque psoriasis","score":0.9190000295639038},{"id":"https://openalex.org/keywords/atopic-dermatitis","display_name":"atopic dermatitis","score":1.0},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.7269999980926514},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.7059999704360962},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.8349999785423279},{"id":"https://openalex.org/keywords/disease-severity-score","display_name":"disease severity index","score":0.7760000228881836},{"id":"https://openalex.org/keywords/pasi","display_name":"PASI","score":0.8420000076293945},{"id":"https://openalex.org/keywords/scorad","display_name":"SCORAD","score":0.8899999856948853},{"id":"https://openalex.org/keywords/salt","display_name":"salt","score":0.9649999737739563}],"concepts":[{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.9775999784469604},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9718999862670898},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.7294999957084656},{"id":"https://openalex.org/C2777524370","wikidata":"https://www.wikidata.org/wiki/Q5075435","display_name":"Alopecia areata","level":2,"score":0.7293000221252441},{"id":"https://openalex.org/C2776233030","wikidata":"https://www.wikidata.org/wiki/Q17149812","display_name":"Janus kinase inhibitor","level":4,"score":0.718500018119812},{"id":"https://openalex.org/C23131810","wikidata":"https://www.wikidata.org/wiki/Q818574","display_name":"Observational study","level":2,"score":0.6827999949455261},{"id":"https://openalex.org/C2778329239","wikidata":"https://www.wikidata.org/wiki/Q268667","display_name":"Atopic dermatitis","level":2,"score":0.661300003528595},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6492999792098999},{"id":"https://openalex.org/C2780564577","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Psoriasis","level":2,"score":0.5376999974250793},{"id":"https://openalex.org/C3020604521","wikidata":"https://www.wikidata.org/wiki/Q179945","display_name":"Plaque psoriasis","level":3,"score":0.5077999830245972},{"id":"https://openalex.org/C2780501606","wikidata":"https://www.wikidata.org/wiki/Q7389221","display_name":"SCORAD","level":4,"score":0.43959999084472656},{"id":"https://openalex.org/C2777011040","wikidata":"https://www.wikidata.org/wiki/Q390643","display_name":"Psoriasis Area and Severity Index","level":3,"score":0.43529999256134033},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.39820000529289246},{"id":"https://openalex.org/C2776260265","wikidata":"https://www.wikidata.org/wiki/Q511097","display_name":"Psoriatic arthritis","level":3,"score":0.3707999885082245},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.3682999908924103},{"id":"https://openalex.org/C112392421","wikidata":"https://www.wikidata.org/wiki/Q903451","display_name":"Janus kinase","level":3,"score":0.3643999993801117},{"id":"https://openalex.org/C2781059491","wikidata":"https://www.wikidata.org/wiki/Q422232","display_name":"Methotrexate","level":2,"score":0.3513000011444092},{"id":"https://openalex.org/C30036603","wikidata":"https://www.wikidata.org/wiki/Q17125150","display_name":"Severity of illness","level":2,"score":0.3447999954223633},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.33880001306533813},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3197000026702881},{"id":"https://openalex.org/C2780401118","wikidata":"https://www.wikidata.org/wiki/Q4734616","display_name":"Alopecia universalis","level":3,"score":0.29660001397132874},{"id":"https://openalex.org/C2780132546","wikidata":"https://www.wikidata.org/wiki/Q348260","display_name":"Adalimumab","level":3,"score":0.2802000045776367},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.27810001373291016},{"id":"https://openalex.org/C201903717","wikidata":"https://www.wikidata.org/wiki/Q1778788","display_name":"Cohort study","level":2,"score":0.26080000400543213}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.4103/ijd.ijd_948_25","doi":"https://doi.org/10.4103/ijd.ijd_948_25","is_oa":true,"landing_page_url":"https://doi.org/10.4103/ijd.ijd_948_25","pdf_url":null,"source":{"id":"https://openalex.org/S40624954","display_name":"Indian Journal of Dermatology","issn_l":"0019-5154","issn":["0019-5154","1998-3611"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320448","host_organization_name":"Medknow","host_organization_lineage":["https://openalex.org/P4310320448","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Medknow","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Indian Journal of Dermatology","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.4103/ijd.ijd_948_25","doi":"https://doi.org/10.4103/ijd.ijd_948_25","is_oa":true,"landing_page_url":"https://doi.org/10.4103/ijd.ijd_948_25","pdf_url":null,"source":{"id":"https://openalex.org/S40624954","display_name":"Indian Journal of Dermatology","issn_l":"0019-5154","issn":["0019-5154","1998-3611"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320448","host_organization_name":"Medknow","host_organization_lineage":["https://openalex.org/P4310320448","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Medknow","Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Indian Journal of Dermatology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W2116158190","https://openalex.org/W2128551077","https://openalex.org/W2548580472","https://openalex.org/W2548627709","https://openalex.org/W2891620699","https://openalex.org/W2945819374","https://openalex.org/W2977918824","https://openalex.org/W3002900940","https://openalex.org/W3007128216","https://openalex.org/W3035515475","https://openalex.org/W3196688555","https://openalex.org/W3209046601","https://openalex.org/W4221127450","https://openalex.org/W4280599398","https://openalex.org/W4285726918","https://openalex.org/W4298088129","https://openalex.org/W4386888562","https://openalex.org/W4388462724","https://openalex.org/W4388641486","https://openalex.org/W4389951253","https://openalex.org/W4393082202","https://openalex.org/W4396869774","https://openalex.org/W4402079350","https://openalex.org/W4402692070","https://openalex.org/W4407207352","https://openalex.org/W4409445439"],"related_works":["https://openalex.org/W2977918824","https://openalex.org/W7161650660","https://openalex.org/W7139949859","https://openalex.org/W2031336753","https://openalex.org/W7131354913","https://openalex.org/W4205908659","https://openalex.org/W2548580472","https://openalex.org/W7155067045","https://openalex.org/W4401153245","https://openalex.org/W2605582956"],"abstract_inverted_index":{"Abstract":[0],"Background:":[1],"Tofacitinib":[2],"is":[3,20],"a":[4,60],"first-generation":[5],"janus":[6],"kinase":[7],"inhibitor":[8],"approved":[9],"for":[10,23,69,77,106,114,121],"rheumatoid":[11],"arthritis,":[12],"psoriatic":[13],"arthritis":[14],"and":[15,29,35,47,51,84,93,111,116,127,131,142,184,196,206,231],"ulcerative":[16],"colitis.":[17],"However,":[18],"it":[19,252],"also":[21,148],"used":[22],"several":[24],"off-label":[25,38,247],"dermatological":[26],"disorders.":[27],"Aims":[28],"Objectives:":[30],"To":[31],"evaluate":[32],"the":[33,75,167,207,246],"effectiveness":[34],"safety":[36],"of":[37,40,103,249],"use":[39,248],"tofacitinib":[41,68,92,165],"in":[42,192,210],"alopecia":[43,81],"areata,":[44],"plaque":[45,85],"psoriasis":[46,86],"atopic":[48,78],"dermatitis.":[49],"Materials":[50],"Methods:":[52],"This":[53,238],"prospective":[54],"observational":[55],"study":[56,168,239],"was":[57],"conducted":[58],"at":[59,125,128],"tertiary":[61],"care":[62],"hospital.":[63],"Patients":[64],"either":[65],"currently":[66],"taking":[67],"\u22642":[70],"weeks":[71],"or":[72],"being":[73],"prescribed":[74],"drug":[76,95,222,235],"dermatitis":[79],"(AD),":[80],"areata":[82],"(AA)":[83],"(PP)":[87],"were":[88,97,147,156,159,200,224],"included.":[89],"Socio-demographic":[90],"profile,":[91],"other":[94],"details":[96],"noted.":[98],"Disease":[99],"severity":[100,213],"scores\u2014SALT":[101],"(Severity":[102],"Alopecia":[104],"Tool)":[105],"AA,":[107],"PASI":[108],"(Psoriasis":[109],"Area":[110],"Severity":[112],"Index)":[113],"PP":[115],"SCORAD":[117,195],"(SCORing":[118],"Atopic":[119],"Dermatitis)":[120],"AD":[122],"patients\u2014were":[123],"recorded":[124],"enrolment":[126],"2,":[129],"4":[130],"8":[132,171,181],"\u00b1":[133,172],"2":[134,173],"weeks\u2019":[135],"visits,":[136],"respectively.":[137,198],"Investigators\u2019":[138],"Global":[139],"Assessment":[140],"(IGA)":[141],"all":[143,211],"treatment-emergent":[144],"adverse":[145,221,259],"effects":[146],"assessed.":[149],"Results:":[150],"Thirty":[151],"patients":[152],"(13-AA;":[153],"9-PP;":[154],"8-AD)":[155],"enrolled.":[157],"All":[158],"on":[160],"5":[161],"mg":[162],"twice":[163],"daily":[164],"during":[166],"course.":[169],"At":[170],"weeks,":[174],"13":[175],"cases":[176,179,182,186],"(100%),":[177],"9":[178],"(77.77%),":[180],"(62.5%)":[183],"30":[185],"(30%)":[187],"achieved":[188],">":[189],"50%":[190],"reduction":[191],"SALT,":[193],"PASI,":[194],"IGA,":[197],"There":[199],"statistically":[201],"significant":[202,216],"differences":[203],"between":[204],"baseline":[205],"follow-up":[208],"visits":[209],"disease":[212],"scores,":[214],"indicating":[215],"clinical":[217],"improvement.":[218],"Twelve":[219],"non-serious":[220,258],"reactions":[223],"noted,":[225],"which":[226],"resolved":[227],"with":[228,256],"symptomatic":[229],"treatment":[230],"did":[232],"not":[233],"require":[234],"discontinuation.":[236],"Conclusion:":[237],"generated":[240],"data":[241],"to":[242],"guide":[243],"clinicians":[244],"regarding":[245],"tofacitinib,":[250],"as":[251],"showed":[253],"promising":[254],"results":[255],"few":[257],"effects.":[260]},"counts_by_year":[],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2026-10-31T00:00:00"}